Breaking News Instant updates and real-time market news.

ACHV

Achieve Life Sciences

$2.66

0.005 (0.19%)

, PFE

Pfizer

$42.51

-0.58 (-1.35%)

08:29
06/14/19
06/14
08:29
06/14/19
08:29

Achieve Life Sciences initiated with a Buy at Maxim

Maxim analyst Jason McCarthy initiated Achieve Life Sciences (ACHV) with a Buy rating and a price target of $6, citing the company's development of a "de-risked" smoking cessation aid cytisinicline. The analyst notes that cytisinicline has been in the Eastern European market since the 1970's but has also recently gained "proof of concept" data with a positive phase 2b study of 54% abstinence following 3mg daily intake vs. 16% for placebo. McCarthy adds that Pfizer's (PFE) competing Chantix generated $838M in revenue in FY18 but covered only about 3% of the U.S. smoking population.

ACHV

Achieve Life Sciences

$2.66

0.005 (0.19%)

PFE

Pfizer

$42.51

-0.58 (-1.35%)

  • 28

    Aug

  • 16

    Sep

ACHV Achieve Life Sciences
$2.66

0.005 (0.19%)

06/11/19
LTCO
06/11/19
NO CHANGE
Target $20
LTCO
Buy
Achieve Life Sciences price target raised to $20 from $12 at Ladenburg
06/11/19
LTCO
06/11/19
NO CHANGE
LTCO
Achieve Life Sciences price target raised to $20 from $12 at Ladenburg
Ladenburg analyst Michael Higgins reiterated a Buy rating on Achieve Life Sciences, and raised his price target to $20 from $12, due to positive clinical trial results in the Phase 2 ORCA-1 trial that the company reported this morning. The analyst added that the most important result was "the secondary endpoint of the quit rates at week 4 and at weeks 5-8, since quit rates are the expected primary endpoint in the upcoming pivotal trials." Higgins encouraged investors to build a position in Achieve at current levels.
06/14/19
MAXM
06/14/19
INITIATION
Target $6
MAXM
Buy
Achieve Life Sciences initiated with a Buy at Maxim
Maxim initiated Achieve Life Sciences with a Buy rating and $6 price target.
PFE Pfizer
$42.51

-0.58 (-1.35%)

05/29/19
CANT
05/29/19
NO CHANGE
Target $53
CANT
Overweight
Pfizer sales potential Vyndaqel/Vyndamax underappreciated, says Cantor
Cantor Fitzgerald analyst Louise Chen says her "quick poll" of cardiologists supports the view that the peak sales potential of Pfizer's Vyndaqel/Vyndamax is underappreciated. The sales could be "meaningfully higher" than the 2024 consensus forecasts of $1.5B given a treatment cost of $225,000 per patient per year and a potential treatment population of 1M-plus in the U.S., Chen tells investors in a research note. She thinks the growing usage of scintigraphy for diagnosing transthyretin amyloid cardiomyopathy will increase the number of patients that are identified and eligible for treatment. The analyst reiterates an Overweight rating on Pfizer with a $53 price target.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
06/04/19
MSCO
06/04/19
INITIATION
Target $48
MSCO
Overweight
Pfizer resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst David Risinger resumed coverage of Pfizer with an Overweight rating and $48 price target, stating that he sees Ibrance and pipeline products driving accelerating growth starting next year. Risinger estimates Pfizer will see 3-yr revenue CAGR of 6% from FY20-23 and EPS growth of 11% over the same period, he tells investors.
06/04/19
06/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) was initiated with an Overweight at Barclays and Morgan Stanley, an Outperform at Oppenheimer, Cowen, William Blair, and JMP Securities, a Buy at Canaccord, SunTrust, Deutsche Bank, Loop Capital, Mizuho, BTIG, Needham, and BofA/Merrill, and a Neutral at Citi. 2. Lyft (LYFT) was initiated with a Buy at BTIG, SunTrust, and Citi, a Hold at Loop Capital, and an Equal Weight at Barclays. 3. Alibaba (BABA), JD.com (JD), and Twitter (TWTR) were initiated with a Buy at Loop Capital, while Alphabet (GOOG, GOOGL) was initiated with a Hold. 4. Pfizer (PFE) was resumed with an Overweight at Morgan Stanley. 5. Neon Therapeutics (NTGN) was initiated with a Buy at Mizuho. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

NRCG

NRC Group

$11.04

2.23 (25.31%)

, ECOL

US Ecology

$57.37

-5.38 (-8.57%)

05:54
06/25/19
06/25
05:54
06/25/19
05:54
Downgrade
NRC Group, US Ecology rating change  »

NRC Group downgraded to…

NRCG

NRC Group

$11.04

2.23 (25.31%)

ECOL

US Ecology

$57.37

-5.38 (-8.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XHR

Xenia Hotels

$20.41

-0.55 (-2.62%)

05:45
06/25/19
06/25
05:45
06/25/19
05:45
Initiation
Xenia Hotels initiated  »

Xenia Hotels initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCE

Arco Platform

$43.38

-2.35 (-5.14%)

05:41
06/25/19
06/25
05:41
06/25/19
05:41
Initiation
Arco Platform initiated  »

Arco Platform initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$129.65

-1.32 (-1.01%)

, EOLS

Evolus

$13.69

0.13 (0.96%)

05:40
06/25/19
06/25
05:40
06/25/19
05:40
Recommendations
Allergan, Evolus analyst commentary at Mizuho »

Allergan price target…

AGN

Allergan

$129.65

-1.32 (-1.01%)

EOLS

Evolus

$13.69

0.13 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

QSR

Restaurant Brands

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Restaurant Brands initiated  »

Restaurant Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$83.65

-0.16 (-0.19%)

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Starbucks initiated  »

Starbucks initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

  • 09

    Jul

DPZ

Domino's Pizza

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Domino's Pizza initiated  »

Domino's Pizza…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 13

    Nov

SHAK

Shake Shack

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Shake Shack initiated  »

Shake Shack initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 09

    Jul

  • 14

    Aug

MCD

McDonald's

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
McDonald's initiated  »

McDonald's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CMG

Chipotle

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Chipotle initiated  »

Chipotle initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

PZZA

Papa John's

$44.13

-0.25 (-0.56%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Papa John's initiated  »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

WEN

Wendy's

$19.15

-0.22 (-1.14%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Wendy's initiated  »

Wendy's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 14

    Aug

  • 13

    Nov

YUM

Yum! Brands

$110.62

0.35 (0.32%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Yum! Brands initiated  »

Yum! Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNKN

Dunkin' Brands

$81.01

1.47 (1.85%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Dunkin' Brands initiated  »

Dunkin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

JACK

Jack in the Box

$82.83

-2.33 (-2.74%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Jack in the Box initiated  »

Jack in the Box initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 08

    Aug

PYX

Pyxus

$13.42

-1.1 (-7.58%)

05:36
06/25/19
06/25
05:36
06/25/19
05:36
Initiation
Pyxus initiated  »

Pyxus initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$137.80

0.86 (0.63%)

, AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

05:30
06/25/19
06/25
05:30
06/25/19
05:30
Recommendations
Microsoft, Amazon.com analyst commentary at Jefferies »

Microsoft Azure likely…

MSFT

Microsoft

$137.80

0.86 (0.63%)

AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

XONE

ExOne

$7.38

-0.21 (-2.77%)

, SIEGY

Siemens

$0.00

(0.00%)

05:28
06/25/19
06/25
05:28
06/25/19
05:28
Hot Stocks
ExOne announces partnership with Siemens »

ExOne (XONE) announced a…

XONE

ExOne

$7.38

-0.21 (-2.77%)

SIEGY

Siemens

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPTN

SpartanNash

$10.87

-0.05 (-0.46%)

05:23
06/25/19
06/25
05:23
06/25/19
05:23
Initiation
SpartanNash initiated  »

SpartanNash initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$9.51

-0.405 (-4.08%)

05:23
06/25/19
06/25
05:23
06/25/19
05:23
Hot Stocks
Almirall exercises option with Dermira to license rights to lebrikizumab in EU »

Almirall and Dermira…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGHF

Telenet

$0.00

(0.00%)

05:15
06/25/19
06/25
05:15
06/25/19
05:15
Downgrade
Telenet rating change  »

Telenet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DK

Delek US

$39.13

-0.635 (-1.60%)

05:14
06/25/19
06/25
05:14
06/25/19
05:14
Downgrade
Delek US rating change  »

Delek US downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.43

1.44 (14.41%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Downgrade
Caesars rating change  »

Caesars downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

GRUB

GrubHub

$72.05

0.91 (1.28%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Upgrade
GrubHub rating change  »

GrubHub upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 09

    Jul

SITE

SiteOne Landscape

$66.97

-0.25 (-0.37%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Upgrade
SiteOne Landscape rating change  »

SiteOne Landscape…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.